Abstract
Background: Programmed cell death protein 1 (PD-1) is a membrane receptor that is expressed on the surface of various immune cells, such as T cells, B cells, monocytes, natural killer T cells, and dendritic cells. In cancer, the interaction between PD-1 and its ligand PD-L1 suppresses the activation and function of T lymphocytes, leading to the impairment and apoptosis of tumor-specific T cells. This mechanism allows cancer cells to evade the immune response and promotes tumor progression.
Methods: Recombinant PD-1 protein was produced and used to immunize a camel. A nanobody library was generated from the camel’s peripheral blood lymphocytes and screened for PD-1 binding. A specific nanobody (3PD9) was selected and characterized by affinity measurement, western blotting, and flow cytometry analysis. The ability of the selected nanobody to block the inhibitory signal of PD-1 in peripheral blood mononuclear cells (PBMCs) was evaluated by measuring the level of interleukin-2 (IL-2).
Results: The selected nanobody showed high specificity and affinity for human PD-1. Western blot and flow cytometry analysis confirmed that 3PD9 could recognize and bind to human PD-1 on the cell surface. It was demonstrated that the level of IL-2 was significantly increased in PBMCs treated with 3PD9 compared to the control group, indicating that the nanobody could enhance the T cell response by disrupting the PD-1/PD-L1 interaction.
Conclusion: The results suggested that the anti-PD-1 nanobody could be a promising candidate for cancer immunotherapy.
Keywords: Single chain antibody, PD-1, interleukin-2, nanobody, immune checkpoint inhibitor, immune cells.
[http://dx.doi.org/10.1186/s12967-014-0373-0] [PMID: 25592115]
[http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331] [PMID: 18173375]
[http://dx.doi.org/10.1084/jem.20112741] [PMID: 22641383]
[http://dx.doi.org/10.1002/j.1460-2075.1992.tb05481.x] [PMID: 1396582]
[http://dx.doi.org/10.1006/geno.1994.1562] [PMID: 7851902]
[http://dx.doi.org/10.4049/jimmunol.1003208] [PMID: 21263073]
[http://dx.doi.org/10.1084/jem.192.7.1027] [PMID: 11015443]
[http://dx.doi.org/10.1073/pnas.1003345107] [PMID: 20385810]
[http://dx.doi.org/10.1007/s10549-013-2581-3] [PMID: 23756627]
[http://dx.doi.org/10.1126/science.aaa8172] [PMID: 25838373]
[http://dx.doi.org/10.1007/s00262-014-1519-x] [PMID: 24514954]
[http://dx.doi.org/10.1158/1078-0432.CCR-16-2677] [PMID: 28855348]
[http://dx.doi.org/10.1186/s12929-017-0329-9] [PMID: 28376884]
[http://dx.doi.org/10.1001/jamaoncol.2016.0639] [PMID: 27310809]
[http://dx.doi.org/10.1128/AAC.45.10.2807-2812.2001] [PMID: 11557473]
[http://dx.doi.org/10.1371/journal.pone.0113688] [PMID: 25419715]
[http://dx.doi.org/10.1007/s11103-013-0118-0] [PMID: 23963604]
[http://dx.doi.org/10.1016/0022-1759(87)90187-6] [PMID: 2439600]
[http://dx.doi.org/10.1038/nprot.2016.169] [PMID: 28079879]
[http://dx.doi.org/10.1002/jcc.20084] [PMID: 15264254]
[http://dx.doi.org/10.1093/protein/8.2.127] [PMID: 7630882]
[http://dx.doi.org/10.5301/jbm.5000063] [PMID: 24425321]
[http://dx.doi.org/10.1038/nm730] [PMID: 12091876]
[http://dx.doi.org/10.1056/NEJMoa1200690] [PMID: 22658127]
[http://dx.doi.org/10.1016/j.bioeng.2007.03.004] [PMID: 17466589]
[http://dx.doi.org/10.1089/1536859041224334] [PMID: 15312305]
[http://dx.doi.org/10.1056/NEJMoa1806311] [PMID: 30625070]
[http://dx.doi.org/10.1007/s40259-019-00392-z]
[http://dx.doi.org/10.1080/10826068.2019.1692217] [PMID: 31799894]
[http://dx.doi.org/10.1016/j.bbrc.2019.08.160] [PMID: 31495493]
[http://dx.doi.org/10.3390/biomedicines8120562] [PMID: 33276580]
[http://dx.doi.org/10.1093/nar/gkab926] [PMID: 34664670]
![Wayfinder Image](/images/wayfinder.jpg)